3.38
前日終値:
$3.65
開ける:
$3.7
24時間の取引高:
488.92K
Relative Volume:
1.41
時価総額:
$215.86M
収益:
$163.78M
当期純損益:
$25.88M
株価収益率:
5.20
EPS:
0.65
ネットキャッシュフロー:
$-28.66M
1週間 パフォーマンス:
-13.55%
1か月 パフォーマンス:
-17.16%
6か月 パフォーマンス:
-42.22%
1年 パフォーマンス:
-63.69%
Voyager Therapeutics Inc Stock (VYGR) Company Profile
名前
Voyager Therapeutics Inc
セクター
電話
857-259-5340
住所
75 HAYDEN AVENUE, LEXINGTON, MA
VYGR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VYGR
Voyager Therapeutics Inc
|
3.38 | 215.86M | 163.78M | 25.88M | -28.66M | 0.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
2024-12-02 | 開始されました | Citigroup | Buy |
2024-11-29 | 再開されました | Wedbush | Outperform |
2024-10-16 | 開始されました | Leerink Partners | Outperform |
2024-03-26 | 開始されました | Guggenheim | Buy |
2024-03-19 | 開始されました | H.C. Wainwright | Buy |
2024-03-07 | 開始されました | Citigroup | Buy |
2024-01-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-05-10 | 開始されました | Truist | Buy |
2023-03-10 | 開始されました | Oppenheimer | Outperform |
2021-10-07 | アップグレード | Robert W. Baird | Neutral → Outperform |
2021-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2021-02-03 | ダウングレード | BTIG Research | Buy → Neutral |
2021-02-03 | ダウングレード | Wedbush | Outperform → Neutral |
2020-12-24 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2020-12-23 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2020-11-11 | ダウングレード | Oppenheimer | Outperform → Perform |
2020-11-10 | ダウングレード | Raymond James | Strong Buy → Outperform |
2020-11-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2020-03-19 | 開始されました | The Benchmark Company | Buy |
2020-02-06 | 開始されました | Oppenheimer | Outperform |
2018-11-15 | アップグレード | Raymond James | Outperform → Strong Buy |
2018-09-10 | 再開されました | BTIG Research | Buy |
2018-09-10 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2018-06-04 | 開始されました | H.C. Wainwright | Buy |
2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
2018-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
2018-02-02 | 開始されました | Morgan Stanley | Overweight |
2017-11-28 | 再開されました | Piper Jaffray | Overweight |
2017-10-31 | 開始されました | Robert W. Baird | Outperform |
2017-10-27 | 開始されました | Canaccord Genuity | Buy |
2017-10-23 | 繰り返されました | Stifel | Buy |
2017-10-12 | 開始されました | Raymond James | Outperform |
2017-08-17 | 開始されました | Evercore ISI | Outperform |
2017-07-28 | 再開されました | Stifel | Buy |
すべてを表示
Voyager Therapeutics Inc (VYGR) 最新ニュース
Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025 - Nasdaq
Voyager Therapeutics stock hits 52-week low at $3.54 By Investing.com - Investing.com UK
Voyager reveals promising Alzheimer’s therapy data By Investing.com - Investing.com Australia
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - GlobeNewswire
New Alzheimer's Breakthrough: Single-Dose Gene Therapy Slashes Tau Levels by 73% - Stock Titan
Voyager Therapeutics at Virtual CNS Forum: Strategic Insights on Neurotherapeutics - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire
Voyager Therapeutics' (VYGR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Canaccord Genuity Group Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00 - Armenian Reporter
Voyager Therapeutics (NASDAQ:VYGR) Earns “Buy” Rating from HC Wainwright - Defense World
Voyager Therapeutics COO Robin Swartz sells $30,927 in stock - MSN
Cantor Fitzgerald Reaffirms “Overweight” Rating for Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates - MSN
H.C. Wainwright maintains $30 target on Voyager Therapeutics stock By Investing.com - Investing.com Canada
Voyager Therapeutics’ Earnings Call Highlights Promising Future - TipRanks
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts - Benzinga
Voyager Therapeutics stock hits 52-week low at $3.67 - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.67 By Investing.com - Investing.com Australia
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo - TipRanks
Voyager Therapeutics Inc earnings missed by $0.22, revenue fell short of estimates - Investing.com
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings - Investing.com Australia
Voyager Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating - TipRanks
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings By Investing.com - Investing.com South Africa
Voyager Therapeutics: Q4 Earnings Snapshot - mySA
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VOYAGER THERAPEUTICS Earnings Results: $VYGR Reports Quarterly Earnings - Nasdaq
Voyager Therapeutics, Inc. SEC 10-K Report - TradingView
Voyager Therapeutics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - TradingView
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire Inc.
VOYAGER THERAPEUTICS Earnings Preview: Recent $VYGR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Increases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast - GlobeNewswire
John Stankey Updates Shareholders at Morgan Stanley Technology, Media & Telecom Conference on March 4 - The Globe and Mail
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach - PharmaVoice
When Will Voyager Therapeutics Reveal Its Latest Neurogenetic Medicine Progress? - StockTitan
Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright - Defense World
Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment - Marketscreener.com
Voyager Therapeutics Reports Positive Data From Single Ascending Dose Study Of VY7523 - Nasdaq
Voyager Therapeutics Reports Positive Topline Data for VY7523 in Alzheimer’s Disease Trials - Nasdaq
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease - The Manila Times
Voyager Reports Positive Topline Data for Single Ascending - GlobeNewswire
Can Voyager's Anti-Tau Antibody Break Through in Alzheimer's Treatment? Phase 1 Results Show Promise - StockTitan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Voyager Therapeutics stock hits 52-week low at $4 - Investing.com India
Voyager Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Voyager Therapeutics Inc (VYGR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):